CRISPR/Cas9 RET Gene Knockout in Medullary Thyroid Carcinoma Cell-lines: Optimization and Validation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Medullary Thyroid Cancer (MTC) is an aggressive carcinoma.
• RET proto-oncogene mutations are implicated in MTC development.
• Targeting RET is a key strategy for MTC treatment.

Purpose of the Study:

• To knock out the RET oncogene in MTC cell lines using CRISPR/Cas9.
• To investigate the effects of RET gene inhibition on MTC cells.
• To evaluate RET signaling pathway modulation.

Main Methods:

• CRISPR/Cas9 genome editing was employed to target the RET gene.
• sgRNAs were designed to target specific RET exons in TT and MZ-CRC-1 cell lines.
• T7EI assay, DNA sequencing, Real-time PCR, and ELISA were used for confirmation and expression analysis.

Main Results:

• CRISPR/Cas9 successfully confirmed RET gene knock-out.
• Significant reduction in RET gene and protein expression observed.
• Increased apoptosis and decreased Calcitonin gene expression in transfected cells.
• Inhibition of downstream signaling proteins including p-PI3K, p-AKT, p-MEK, and p-ERK.

Conclusions:

• First-time successful RET gene knock-out using CRISPR/Cas9 in MTC cells.
• Inhibition of RET signaling pathway offers a specific therapeutic target.
• Potential for personalized medicine approaches in RET-driven diseases.